seri
tricycl
penciclovir
pcv
hydroxybutylguanin
hbg
deriv
prepar
enhanc
lipophil
follow
effici
synthet
rout
novel
tricycl
deriv
evalu
inhibitori
activ
herp
simplex
viru
thymidin
kinas
defici
acv
resist
tricycl
hbg
deriv
devoid
inhibitori
activ
howev
sever
tricycl
pcv
deriv
show
promis
antivir
activ
particular
r
h
display
good
inhibitori
activ
ec
ec
retain
inhibitori
activ
tk
cell
ec
comput
dock
experi
support
biolog
data
observ
preliminari
studi
provid
use
data
develop
tricycl
acycl
nucleosid
deriv
improv
lipophil
retent
activ
tk
defici
strain
also
new
tricycl
deriv
evalu
broad
rang
dna
rna
virus
found
inact
subtox
concentr
addit
weak
moder
cytostat
effect
observ
new
compound
vv
give
product
white
solid
yield
g
mp
tlc
ch
cl
meoh
vv
rf
h
nmr
dmsod
quint
j
hz
quint
j
hz
q
j
hz
j
hz
j
hz
oh
j
hf
hz
dd
j
hf
hz
j
hz
br
herp
simplex
viru
hsv
like
herp
virus
establish
lifelong
latenc
follow
primari
infect
hsvassoci
diseas
rang
mild
orolabi
ulcer
cold
sore
sever
enceph
herp
simplex
virus
categoris
two
type
mainli
transmit
oralor
contact
result
mainli
cold
sore
mainli
sexual
transmit
result
common
infect
genit
herp
global
two
third
popul
age
estim
infect
herp
simplex
enceph
hse
common
caus
sporad
fatal
viral
enceph
account
almost
case
enceph
hse
present
acut
focal
necrotis
infect
brain
untreat
mortal
rate
first
line
treatment
hse
aciclovir
acv
administ
intraven
day
howev
even
treat
hse
associ
mortal
rate
perman
neurolog
damag
limit
acv
therapi
hse
develop
viral
resist
low
cn
uptak
tricycl
acv
ganciclovir
gcv
deriv
fig
shown
effect
inhibitor
thymidin
kinas
tk
interest
maintain
inhibitori
activ
enzym
lipophil
current
medic
may
valuabl
agent
treatment
cn
infect
moreov
tricycl
compound
found
exhibit
strong
intrins
fluoresc
properti
allow
sensit
concentr
monitor
optim
therapeut
dose
penciclovir
pcv
hydroxybutylguanin
hbg
fig
carbocycl
analogu
gcv
acv
respect
spectrum
activ
pcv
human
herpesvirus
found
similar
acv
howev
certain
circumst
pcv
activ
acv
owe
higher
stabil
pcvtp
infect
cell
rel
acvtp
also
concentr
confirm
pcv
like
acv
highli
select
subsequ
exhibit
toxic
cell
cultur
similarli
hbg
report
higher
affin
tk
acv
addit
rel
compar
select
inhibit
viral
dna
synthesi
good
safeti
profil
cell
http
receiv
decemb
receiv
revis
form
januari
accept
februari
cultur
applic
tricycl
scaffold
modif
pcv
hbg
interest
determin
whether
antivir
activ
maintain
importantli
modif
nucleobas
moieti
addit
ring
may
result
benefici
physicochem
properti
enhanc
lipophil
fluoresc
andor
enhanc
enzym
bind
interact
librari
tricycl
pcv
hbg
deriv
fig
design
synthesis
evalu
antivir
activ
studi
structureact
relationship
support
comput
dock
analysi
pcv
hbg
prepar
previous
describ
reaction
subsequ
acid
hydrolysi
protect
deriv
scheme
new
tricycl
analogu
pcv
hbg
hydroxymethyl
butyl
aryl
aryl
obtain
upon
reaction
sodium
salt
pcv
hbg
gener
situ
treatment
nah
appropri
bromoketon
yield
tabl
new
compound
purifi
flash
column
chromatographi
use
gradient
elut
mixtur
ch
cl
meoh
follow
recrystallis
scheme
procedur
use
prepar
new
deriv
mostli
follow
previous
report
method
prepar
analog
modifi
guanosin
tricycl
deriv
tricycl
deriv
show
sensit
toward
light
air
protect
wrap
foil
rapid
storag
amber
colour
vial
group
highli
unstabl
light
air
case
pcv
deriv
decompos
rapidli
collect
convers
hbg
congen
stabl
enough
collect
safe
tricycl
compound
screen
inhibitor
hsv
use
herp
simplex
ko
strain
herp
simplex
g
strain
thymidin
kinas
defici
aciclovir
resist
herp
simplex
tkko
acv
r
strain
human
embryon
lung
hel
cell
none
tricycl
hbg
deriv
show
inhibitori
activ
ec
cytotox
howev
tricycl
pcv
deriv
exhibit
antiherpet
activ
tabl
newli
synthesis
tricycl
pcv
deriv
compound
inact
antivir
agent
compound
show
activ
rel
high
concentr
ec
respect
compound
show
moder
activ
ec
respect
wherea
activ
inhibitori
replic
ec
respect
similar
result
among
synthesis
tricycl
pcv
compound
compound
activ
strain
show
mark
inhibit
ec
respect
also
compound
show
moder
activ
strain
ec
wherea
remain
compound
show
activ
strain
two
compound
retain
activ
tk
acv
resist
strain
tricycl
deriv
compound
show
potent
inhibitori
activ
tk
ec
wherea
compound
moder
activ
tk
ec
data
suggest
case
resist
strain
tk
compound
independ
viral
tk
catalys
phosphoryl
antivir
activ
andor
may
use
differ
metabol
activ
pathway
andor
display
uniqu
mechan
antivir
action
unmetabolis
nucleosid
analogu
addit
hsv
tricycl
deriv
screen
broad
rang
dna
rna
virus
includ
vaccinia
viru
human
coronaviru
human
cytomegaloviru
hcmv
strain
davi
strain
varicellazost
viru
tk
vzv
oka
strain
tk
vzv
strain
vesicular
stomat
viru
coxsacki
viru
respiratori
syncyti
viru
viru
sindbi
viru
punta
toro
viru
yellow
fever
viru
influenza
viru
h
n
h
n
subtyp
influenza
b
viru
compound
display
inhibitori
activ
vzv
hcmv
tabl
r
cf
c
h
show
weak
inhibitori
activ
cytomegaloviru
strain
davi
strain
ec
respect
compar
gcv
refer
compound
ec
respect
tk
vzv
oka
strain
ec
r
hoc
h
show
inhibitori
activ
varicellazost
viru
tk
vzv
oka
strain
tk
vzv
strain
ec
respect
compar
acv
refer
compound
ec
respect
display
minim
activ
vzv
tk
strain
oka
ec
note
contrast
hsv
hbg
prove
inact
hcmv
poorli
inhibit
vzv
tk
strain
ec
pcv
inhibitori
hcmv
inhibit
vzv
ec
valu
compar
acv
ie
respect
tk
tkvzv
strain
tabl
new
compound
screen
potenti
cytostat
activ
eight
human
cancer
cell
line
cytostat
inhibitori
concentr
ic
caus
decreas
cell
prolifer
determin
retina
noncancer
htert
pancreat
adenocarcinoma
chronic
myeloid
leukaemia
lung
carcinoma
acut
lymphoblast
leukaemia
acut
myeloid
leukaemia
chronic
myeloid
leukaemia
nonhodgkin
lymphoma
tabl
among
tricycl
pcv
deriv
compound
r
cf
c
h
r
c
h
oc
h
show
moder
cytostat
activ
least
six
cell
line
rang
respect
tricycl
hbg
deriv
gener
inact
display
weak
cytostat
activ
tricycl
hbg
scheme
reagent
condit
k
co
dmf
rt
h
synthesi
h
synthesi
ii
aqueou
hcl
h
b
aqueou
naoh
h
iii
aqueou
hcl
thf
overnight
b
aqueou
naoh
h
iv
nah
dmf
rt
h
tabl
inhibitori
activ
tricycl
pcv
deriv
hsv
cytotox
data
grey
shade
highlight
interest
data
requir
reduc
virusinduc
cytopathogen
b
requir
caus
microscop
detect
alter
normal
cell
morpholog
aciclovir
acv
brivudin
bvdu
cidofovir
cdv
ganciclovir
gcv
inhibitori
activ
tricycl
pcv
deriv
vzv
hcmv
cytotox
data
grey
shade
highlight
interest
data
requir
reduc
virusinduc
cytopathogen
hcmv
plaqu
format
vzv
b
requir
caus
microscop
detect
alter
normal
cell
morpholog
aciclovir
acv
brivudin
bvdu
cidofovir
cdv
ganciclovir
gcv
nd
determin
deriv
trifluoromethyl
aryl
deriv
hbg
r
cf
c
h
effect
rang
cancer
cell
line
prolifer
pancreat
adenocarcinoma
cell
line
slightli
inhibit
new
tricycl
compound
well
parent
compound
pcv
hbg
tabl
molecular
model
compound
perform
use
molecular
oper
environ
moe
softwar
crystal
structur
thymidin
kinas
cocrystallis
pcv
pdb
hbpg
pdb
crystal
structur
tk
includ
atp
molecul
sulphat
ion
observ
suppos
posit
atp
therefor
distanc
oh
acycl
chain
measur
give
idea
proper
orient
ligand
within
activ
site
possibl
compound
acycl
oh
phosphoryl
enzym
result
indic
pcv
analogu
display
distanc
rang
compar
pcv
tk
pocket
predomin
lipophil
sever
region
hydrophil
pcv
hbpg
probe
space
enzym
activ
site
manner
maintain
base
moieti
guanin
acycl
sugar
hydroxyl
group
good
geometri
overal
dock
result
reveal
import
interact
bind
refer
ligand
pcv
hbpg
within
activ
site
fig
base
moieti
lie
locat
stack
make
hydrophob
interact
amino
acid
residu
also
hbond
interact
observ
carbonyl
group
well
top
ring
nitrogen
acycl
sugar
moieti
form
two
import
hbond
interact
amino
acid
residu
fig
tricycl
pcv
compound
lead
interact
addit
amino
acid
amongst
new
compound
observ
interact
activ
compound
r
h
h
close
mimic
interact
observ
pcv
bind
howev
rather
h
h
form
hbond
interact
waterbridg
hbond
fig
moder
activ
fluoro
substitut
analogu
show
almost
similar
bind
mode
although
small
fluoro
substitu
better
dock
within
base
pocket
tricycl
moieti
form
interact
tricycl
purin
moieti
longer
guanin
base
pcv
orient
impact
geometri
acycl
hydroxyl
group
henc
stabil
form
complex
phosphoryl
pcv
analogu
rel
bulki
ether
moieti
h
h
h
oc
h
form
weak
interact
within
acycl
sugar
bind
pocket
addit
steric
clash
observ
case
compound
steric
effect
might
consequ
diminish
abolish
complex
stabil
analysi
dock
hbg
analogu
compar
hbpg
suggest
ligand
like
compet
two
differ
bind
orient
within
activ
site
one
orient
tricycl
base
moieti
stack
carbonyl
group
form
hbond
acycl
hydroxyl
group
situat
sulphat
group
hpbg
donat
hbond
andor
accept
water
bridg
hbond
also
deriv
donat
hbond
fig
orient
tricycl
structur
lie
locat
allow
stack
interact
carbonyl
group
upturn
accept
hbond
andor
waterbridg
hbond
contrast
acycl
hydroxyl
group
second
ligand
orient
away
sulphat
compar
former
orient
accept
hbond
fig
orient
contribut
ligand
bind
observ
group
result
flexibl
weaker
bind
whole
compound
within
activ
site
compar
antivir
activ
compound
structur
provid
insight
function
group
may
benefici
toward
inhibitori
activ
sar
studi
suggest
dihydroxyl
acycl
sugar
moieti
essenti
activ
pcv
deriv
activ
retain
hydrogen
bond
form
group
tricycl
ring
howev
size
hydrogen
bond
form
group
limit
larger
group
induc
steric
effect
exhibit
appar
impact
activ
support
molecular
dock
fig
new
tricycl
analogu
pcv
hbg
carbocycl
analogu
previous
report
tricycl
analogu
gcv
acv
fig
tricycl
acv
gcv
deriv
inhibitori
activ
gener
compar
howev
activ
retain
tk
ko
acv
r
strain
replac
oxygen
acycl
chain
tricycl
acv
analogu
carbon
new
tricycl
hbg
deriv
abolish
activ
highlight
prefer
rather
ch
acycl
chain
tricycl
guanin
deriv
case
tricycl
pcv
deriv
activ
gener
decreas
notic
howev
activ
retain
tricycl
pcv
deriv
r
h
r
h
r
h
group
discuss
present
studi
importantli
two
tricycl
pcv
deriv
r
h
r
h
group
activ
retain
acv
resist
tk
ko
strain
observ
tricycl
gcv
compound
preliminari
studi
provid
use
data
develop
tricycl
acycl
nucleosid
deriv
improv
lipophil
retent
activ
tk
defici
strain
reagent
solvent
gener
purpos
analyt
grade
purchas
sigmaaldrich
ltd
fisher
scientif
fluka
acro
h
c
f
nmr
spectra
record
bruker
avanc
spectromet
oper
mhz
respect
si
intern
standard
element
analysi
perform
compound
medac
ltd
chobham
surrey
uk
high
resolut
mass
spectra
hrm
determin
compound
epsrc
nation
mass
spectrometri
facil
swansea
univers
medac
ltd
chobham
surrey
uk
use
esi
electrospray
ionis
flash
column
chromatographi
perform
silica
gel
mesh
merck
tlc
carri
precoat
silica
plate
kiesel
gel
f
bdh
compound
visualis
illumin
uv
light
nm
melt
point
determin
electrotherm
instrument
uncorrect
solvent
dri
prior
use
store
molecular
siev
nitrogen
compound
pure
follow
compound
prepar
previous
describ
pcv
hbg
suspens
penciclovir
hydroxybutylguanin
g
mmol
mmol
respect
dri
dimethylformamid
ml
sodium
hydrid
suspens
miner
oil
eq
ad
reaction
stir
room
temperatur
h
bromoketon
eq
ad
reaction
stir
h
aqueou
ammonia
solut
ml
ad
quench
reaction
concentr
reduc
pressur
residu
oil
purifi
flash
column
chromatographi
use
gradient
elut
ch
cl
meoh
obtain
product
recrystallis
mixtur
ch
cl
meoh
antivir
assay
base
inhibit
virusinduc
cytopath
plaqu
format
hel
herp
simplex
viru
ko
g
viru
vesicular
stomat
viru
cytomegaloviru
hcmv
varicellazost
viru
vzv
human
corona
viru
vero
sindbisviru
coxsacki
hela
vesicular
stomat
viru
coxsacki
viru
respiratorysyncyti
viru
mdck
influenza
influenza
b
cell
cultur
confluent
cell
cultur
nearli
confluent
mdck
cell
microtit
plate
inocul
ccid
viru
ccid
viru
dose
infect
cell
cultur
plaqueform
unit
pfu
h
viru
adsorpt
period
residu
viru
remov
cell
cultur
incub
presenc
vari
concentr
test
compound
viral
cytopath
record
soon
reach
complet
control
virusinfect
cell
cultur
treat
test
compound
antivir
activ
express
ec
effect
concentr
compound
concentr
requir
reduc
virusinduc
cytopathogen
viral
plaqu
format
mcc
minim
cytotox
concentr
valu
determin
compound
concentr
requir
afford
microscop
visibl
alter
cell
morpholog
new
compound
screen
potenti
cytostat
activ
eight
human
cancer
cell
line
cytostat
inhibitori
concentr
ic
caus
decreas
cell
proliferationrel
number
cell
untreat
control
determin
retina
non
cancer
htert
pancreat
chronic
myeloid
leukaemia
lung
carcinoma
acut
lymphoblast
leukaemia
acut
myeloid
leukaemia
chronic
myeloid
leukaemia
nonhodgkin
lymphoma
dock
studi
perform
use
moe
crystal
structur
thymidin
kinas
cocrystallis
pcv
pdb
hbpg
pdb
minimis
perform
moe
rmsd
gradient
kcalmola
forcefield
partial
charg
automat
calcul
alpha
triangl
placement
deriv
pose
random
superposit
ligand
atom
triplet
alpha
sphere
dummi
receptor
site
chosen
determin
pose
london
score
function
estim
free
energi
bind
ligand
given
pose
refin
result
done
use
forcefield
rescor
refin
result
use
london
score
function
appli
output
databas
dock
file
creat
differ
pose
ligand
arrang
accord
final
score
function
score
last
stage
set
zero
